
zzso of zzso charged zzso to factor zzso zzso a zzso change such that it becomes a zzso for trace amounts of activated factor present in plasma (less than zzso As activated factor zzso zzso zzso or factor zzso forms, it converts zzso zzso to zzso and zzso zzso high molecular weight zzso zzso to release zzso A far more rapid zzso of the remaining zzso factor zzso occurs by zzso zzso by zzso zzso and sequential zzso yields two forms of activated factor zzso zzso factor zzso followed by factor zzso zzso zzso zzso zzso zzso bound to zzso and binding zzso a zzso change in zzso so that it acquires zzso activity and can zzso cleave zzso to produce zzso This reaction is prevented from occurring in plasma by the presence of C1 inhibitor zzso zzso The same active site leads to zzso of the zzso complex to generate zzso if a zzso containing buffer is zzso zzso formation of zzso by this factor zzso route can activate zzso factor zzso to generate factor zzso resulting in a marked increase in the rate of zzso formation as zzso reactions are replaced by zzso zzso zzso zzso binding of the constituents of the zzso cascade to the surface of zzso cells is zzso by zzso and zzso complexes of zzso 1 and zzso zzso zzso zzso zzso zzso Factor zzso and zzso compete for binding to free zzso zzso in zzso while zzso zzso zzso binds factor zzso and zzso 1 zzso binds zzso zzso of factor zzso can be initiated as a result of binding to zzso but is prevented by C1 zzso Yet zzso zzso of zzso to yield zzso in the absence of factor zzso can be initiated by heat shock protein 90 zzso which forms a zzso zzso complex by binding to zzso Thus, zzso zzso zzso can be initiated by zzso of factor zzso or by zzso of zzso zzso zzso zzso types I and II, are due to zzso dominant zzso of the C1 zzso zzso In type I disease, the level of C1 zzso protein and function is zzso low, while type II disease has a normal protein level but diminished zzso There is zzso of the one normal gene so that functional levels are zzso or less and severe zzso affecting peripheral structures, the gastrointestinal zzso and the zzso zzso zzso incubation of plasma of zzso patients (but not normal zzso leads to zzso formation and conversion of zzso to zzso which is reversed by zzso with C1 zzso The disorder can be treated by C1 zzso replacement, zzso of plasma zzso or blockade at the zzso B-2 zzso A recently described zzso with normal C1 zzso (based on zzso of activated zzso presents zzso the zzso is not yet clear, however one-third of patients have a zzso factor zzso zzso We have shown that this zzso has a zzso in zzso overproduction whether the factor zzso zzso is present or not, that patients' C1 zzso is capable of zzso factor zzso and zzso (and not just activated C1) but the functional level is approximately zzso of normal, and that zzso zzso protein levels are zzso In zzso abnormalities can be suppressed by raising C1 zzso to twice normal zzso Finally, zzso proteins have been shown to activate the zzso zzso by catalyzing factor zzso zzso Those include the zzso zzso protein of Alzheimer's disease and zzso This may represent a new avenue for zzso research in human zzso In zzso zzso perhaps other mast zzso zzso the zzso zzso of mast cells, liberated along with zzso also catalyze factor zzso zzso 

